METHOD FOR PRODUCING HUMAN T-CELL RECEPTOR SPECIFIC TO EPITOPE 112-120 (KVAELVHFL) OF MAGE-A3 RECEPTOR Russian patent published in 2025 - IPC C07K14/725 C12N15/867 C12N5/783 

FIELD: biotechnology; immunology.

SUBSTANCE: what is presented is a method for producing a human T-cell receptor specific to KVAELVHFL epitope (112-120) produced of MAGE-A3 protein. Peripheral blood mononuclear cells of relatively healthy HLA-A02+ donors are recovered and divided into adherent and non-adhesive fractions. An adherent fraction is cultivated with recombinant human GM-CSF and IL-4. A dendritic cell culture is obtained, incubated with addition of a priming factor – KVAELVHFL epitope. Method includes adding TNF-α to complete the maturation of dendritic cells, which are then co-cultured with autologous CD8+ T cells, anti-CD3 and anti-CD28 antibodies, IL-2, IL-7 and IL-15. Antigen-specific CD8+ T-cells are recovered, TCR clones are selected on the basis of their affinity, phenotype and specificity. A TCR gene sequence is identified by full-length TCR sequencing, including CDR3. A HIV-1 lentiviral vector carrying the TCR gene is constructed to produce one dominant TCR with alpha and beta chain from the same cell.

EFFECT: invention provides more accurate information on the structure and affinity of human TCR, having high affinity and specificity to the target peptide in a short period of time, which reduces the risk of developing side reactions.

1 cl, 4 dwg